Eli Lilly (LLY) Offering Possible 13.38% Return Over the Next 16 Calendar Days

view original post

Eli Lilly’s most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $245.00 short put and a strike $240.00 long put offers a potential 13.38% return on risk over the next 16 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $245.00 by expiration. The full premium credit of $0.59 would be kept by the premium seller. The risk of $4.41 would be incurred if the stock dropped below the $240.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.

The RSI indicator is at 75.41 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Eli Lilly

UPDATE 1-U.S. buys more doses of Lilly’s COVID-19 treatment for $1.29 bln
Tue, 02 Nov 2021 11:29:09 +0000
Eli Lilly and Co said on Tuesday that the U.S. government bought 614,000 additional doses of its COVID-19 antibody therapy for $1.29 billion. The U.S. Food and Drug Administration in September revised its emergency use authorization for the company’s cocktail, bamlanivimab and etesevimab, to include for use in patients who have been exposed to the virus and are at high risk for progression to severe disease. Under the deal, Lilly will supply a minimum of 400,000 doses of its treatment by Dec. 31 and the rest by Jan. 31.

Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19
Tue, 02 Nov 2021 10:45:00 +0000
Eli Lilly and Company (NYSE: LLY) today announced an additional purchase by the U.S. government for bamlanivimab with etesevimab for administration together. This neutralizing antibody therapy is authorized for emergency use for the treatment of mild to moderate COVID-19 or for post-exposure prophylaxis of COVID-19 in certain individuals. As part of the agreement, Lilly will supply 614,000 doses of bamlanivimab with etesevimab no later than January 31, 2022 for a total of $1.29 billion. A minimu

Lilly to Participate in Bernstein’s Second Annual Operational Decisions Conference
Mon, 01 Nov 2021 16:00:00 +0000
Eli Lilly and Company (NYSE: LLY) will participate in Bernstein’s Second Annual Operational Decisions Conference on Thursday, Nov. 4, 2021. Jake Van Naarden, CEO of Loxo Oncology at Lilly and president of Lilly Oncology; Mark Mintun, senior vice president, research and development – neuroscience, and president, Avid Radiopharmaceuticals; and Jamie Croaning, global development leader – tirzepatide, will participate in a virtual fireside chat at 12:30 p.m., Eastern time.

The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, Sony, American Express and Southern Company
Mon, 01 Nov 2021 12:30:12 +0000
The Zacks Analyst Blog Highlights: Alphabet, Eli Lilly, Sony, American Express and Southern Company

What Is the Nifty 50?
Mon, 01 Nov 2021 02:26:16 +0000
The Nifty 50 was a group of the most popular large-cap stocks on the NYSE in the 1960s and 1970s. Today it refers to an index on India’s stock exchange.

Be Sociable, Share!

Related Posts